News
Extension of the postponement of the settlement of Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2022 financial results on Wednesday, August 3rd, before the market opens. A conference call has been scheduled
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO)(NASDAQ:NBTX)
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: w
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter of 2022.
Press release date / time: Wednesday, July 27, shortly after 22:05
Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today communicates additional preliminary data
Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Pharnext Appoints Antoine Gravelle as General Counsel
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Novocure to Report Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management
Newron Extends Senior Management Team and Strengthens Commitment to ESG
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
DGAP-News: Formycon Reports on Virtual Annual General Meeting 2022